Top 35 Global Companies in Pancreatic Cancer Diagnostic Market 2025: Strategic Overview and Future Trends (2024–2035)

Description

According to a research report published by Spherical Insights & Consulting, The Global Pancreatic Cancer Diagnostic Market Size is projected to Grow from USD 2.65 Billion in 2024 to USD 5.31 Billion by 2035, at a CAGR of 6.52% during the forecast period 2025–2035. The primary drivers propelling the global market are the rising incidence of pancreatic cancer and the increased awareness of early illness detection.

 

Introduction

Pancreatic cancer diagnosis refers to the early discovery and treatment of this aggressive illness. Pancreatic cancer is diagnosed using a variety of procedures, including imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasonography. The market for pancreatic cancer diagnostics is expanding as a result of improved diagnostic technology, higher awareness, and an increase in disease prevalence. The importance of early detection in enhancing treatment results has led to investments in accurate screening instruments, including molecular diagnostics and biomarker testing. With programs like a USD 10.5 million award for early detection methods, groups like the Pancreatic Cancer Action Network are providing funds for research and development. Diagnostic accuracy is improved by innovations like AI-based imaging and pathology tools, and the lab-on-a-chip plasma test from Biological Dynamics. Around the world, governments and health organisations, including the CDC and WHO, are encouraging early screening initiatives and awareness. For instance, early oncology diagnosis methods were introduced in the UK in 2018. For the diagnosis of cancer in its early stages, molecular diagnostics such as liquid biopsies that detect tumour DNA are also becoming more popular. Strategic partnerships and these advancements are fuelling the need for sensitive and dependable pancreatic cancer diagnostic methods, enabling prompt diagnosis and higher survival rates. Through clinical and technological innovation, the market is set to continue growing.

 

Navigate Future Markets with Confidence: Insights from Spherical Insights LLP

The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.

 

Unlock exclusive market insights-Download the Brochure now and dive deeper into the future of the Pancreatic Cancer Diagnostic Market.

 

Pancreatic Cancer Diagnostic Market Size & Statistics

• The Market Size for Pancreatic Cancer Diagnostic Was Estimated to be worth USD 2.65 Billion in 2024.
• The Market Size is Going to Expand at a CAGR of 6.52% between 2025 and 2035.
• The Global Pancreatic Cancer Diagnostic Market Size is anticipated to reach USD 5.31 Billion by 2035.
• North America is expected to generate the highest demand during the forecast period in the Pancreatic Cancer Diagnostic Market
• Asia Pacific is expected to grow the fastest during the forecast period in the Pancreatic Cancer Diagnostic Market.

Regional growth and demand

Asia Pacific is expected to grow the fastest during the forecast period in the pancreatic cancer diagnostic market. The market for pancreatic cancer diagnostics is anticipated to expand at the fastest rate in the Asia Pacific because of rising cancer prevalence, increased awareness of early detection, and rising healthcare spending. Growth is also fuelled by enhancing healthcare infrastructure, increasing access to cutting-edge diagnostics, and encouraging government programs. Furthermore, the market is expanding faster in emerging economies like China, India, and Southeast Asian countries due to a high ageing population, growing usage of AI and molecular diagnostics, and growing partnerships between international corporations and local healthcare institutions.

 

North America is expected to generate the highest demand during the forecast period in the pancreatic cancer diagnostic market. The increased prevalence of the target disease and growing efforts by for-profit and nonprofit organisations to encourage early disease identification are driving the North American region's growth. One prominent organisation that encourages research and raises awareness of the disease is the Pancreatic Cancer Action Network. Furthermore, another element bolstering the expansion of the regional market is the existence of major market participants and the different strategic initiatives they have implemented. In the regional market, for example, Abbott, Agilent Technologies, Inc., and Laboratory Corporation of America Holdings are well-established. Additionally, it is anticipated that favourable reimbursement policies and the growing demand for innovative diagnostic tests will boost market expansion in North America.

 

Top 10 trends in the Pancreatic Cancer Diagnostic Market

1. Rise in Early Detection Initiatives
2. Advancements in Molecular Diagnostics
3. Adoption of Liquid Biopsy and Biomarker Testing
4. Integration of Artificial Intelligence in Diagnostics
5. Increased Funding for R&D and Clinical Trials
6. Growth of Non-Invasive and Lab-on-a-Chip Technologies
7. Government and NGO-Led Awareness Campaigns
8. Expansion of Genetic and Genomic Testing
9. Collaborations Between Pharma and Diagnostic Companies
10. Strong Market Growth in the Asia-Pacific Region

 

1. Rise in Early Detection Initiatives

In an effort to increase survival rates, healthcare systems and organisations are giving priority to early detection initiatives. The promotion of routine screening, public health initiatives, and high-risk group monitoring is raising demand for precise, early-stage diagnostic instruments and broadening the market for early detection products.

 

2. Advancements in Molecular Diagnostics

The accurate identification of genetic alterations and biomarkers linked to pancreatic cancer is made possible by molecular diagnostics. These developments are essential tools in contemporary cancer diagnostics because they increase diagnostic accuracy, facilitate individualised treatment regimens, and enable earlier disease diagnosis, particularly in high-risk groups.

 

3. Adoption of Liquid Biopsy and Biomarker Testing

Non-invasive liquid biopsies provide early and precise cancer detection by identifying circulating tumour DNA and biomarkers in blood or plasma. By facilitating real-time disease monitoring and decreasing the need for surgical biopsies, their increasing clinical acceptance and patient convenience are revolutionising the diagnosis of pancreatic cancer.

 

4. Integration of Artificial Intelligence in Diagnostics

AI improves the interpretation of images, spots minute patterns, and aids in pathology and endoscopic ultrasound decision-making. By increasing speed, accuracy, and early lesion detection, its use in pancreatic cancer diagnostics enhances human competence and greatly improves diagnostic workflows and patient outcomes.

 

5. Increased Funding for R&D and Clinical Trials

In order to encourage the development of new tests and clinical validation, the public and private sectors are increasing their spending on pancreatic cancer research. Funding promotes quicker regulatory approval for sophisticated diagnostic instruments and early-stage detection platforms, increases access to cutting-edge technologies, and speeds up innovation.

 

Empower your strategic planning:

Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the pancreatic cancer diagnostic market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report. 

 

Top 13 Companies Leading the Pancreatic Cancer Diagnostic Market

1. Thermo Fisher Scientific, Inc.
2. QIAGEN
3. Illumina, Inc.
4. F. Hoffmann-La Roche Ltd.
5. Agilent Technologies, Inc.
6. Myriad Genetics, Inc.
7. Koninklijke Philips N.V.
8. Abbott
9. Hitachi, Ltd.
10. Danaher
11. Prestige Biopharma Ltd.
12. BioMarker Strategies
13. Asuragen, Inc.
14. Others

 

1. Thermo Fisher Scientific, Inc.

Headquarters: Waltham, Massachusetts, USA

Thermo Fisher Scientific, Inc. is a world leader in diagnostics, life sciences solutions, and scientific apparatus. The business provides next-generation sequencing (NGS), biomarker assays, and sophisticated molecular diagnostic tools that are essential for the early detection and tracking of pancreatic cancer. Its tools enhance the discovery of mutations linked to cancer, support precision diagnostics, and allow genetic and genomic profiling. Globally, hospitals, clinical labs, and research institutes use Thermo Fisher's platforms extensively, which promote innovation in oncology diagnosis. With a strong focus on research and development, the company uses data-driven diagnostic technologies to improve individualised treatment plans and speed up early cancer detection.

 

2. QIAGEN

Headquarters: Hilden, Germany

QIAGEN is a prominent worldwide supplier of sample and assay technology for research, applied testing, and molecular diagnostics. For the early identification and analysis of pancreatic cancer, the company provides a wide range of options, such as next-generation sequencing (NGS) workflows, liquid biopsy instruments, and PCR-based tests. QIAGEN's diagnostic systems facilitate the detection of genetic mutations, tumour DNA, and cancer biomarkers, allowing for extremely accurate and non-invasive screening. By means of advancements such as QIAcuity digital PCR and QIAseq panels, QIAGEN enables researchers and clinicians to enhance precision medicine and improve pancreatic cancer care outcomes.

 

3. Illumina, Inc.

Headquarters: San Diego, California, USA

Illumina, Inc. is essential to the development of pancreatic cancer precision diagnostics. The company's next-generation sequencing (NGS) systems allow for liquid biopsy analysis of circulating tumour DNA (ctDNA), detection of tumour mutations, and thorough genomic profiling. High-throughput solutions from Illumina provide monitoring, early detection, and individualised treatment plans. Illumina, which is widely used in clinical and research settings, gives medical professionals profound molecular insights that speed up cancer diagnostic innovation and help patients with pancreatic cancer throughout the world achieve better results.

 

4. F. Hoffmann-La Roche Ltd.

Headquarters: Basel, Switzerland

F. Hoffmann-La Roche Ltd. is well-known for its pharmaceutical and diagnostic advancements. Roche provides cutting-edge molecular and immunoassay-based diagnostic techniques for the early identification and surveillance of pancreatic cancer through its diagnostics division. Real-time PCR systems, liquid biopsy platforms, and biomarker assays are important technologies that make accurate and non-invasive cancer screening possible. In pancreatic oncology, Roche's dedication to precision medicine and its integrated strategy, which connects diagnostics with targeted therapies, support earlier diagnosis, more individualised treatment, and better patient outcomes.

 

5. Agilent Technologies, Inc.

Headquarters: Santa Clara, California, USA

Agilent Technologies, Inc. is a world leader in analytical equipment, diagnostics, and life sciences, providing cutting-edge solutions for clinical diagnostics and cancer research. Agilent offers vital tools in the fight against pancreatic cancer, including biomarker analysis methods, immunohistochemistry (IHC) assays, and genomics platforms. These solutions facilitate molecular diagnostics, tumour profiling, and early detection. With the aid of Agilent's advancements in tissue analysis, gene expression, and precision oncology, labs and medical professionals can find mutations unique to cancer, leading to more precise diagnoses and individualised treatment plans for pancreatic cancer patients.

 

Are you ready to discover more about the Pancreatic Cancer Diagnostic market?

The report provides an in-depth analysis of the leading companies operating in the global pancreatic cancer diagnostic market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:

 

Company Profiles

1. Thermo Fisher Scientific, Inc.

• Business Overview
• Company Snapshot
• Products Overview
• Company Market Share Analysis
• Company Coverage Portfolio
• Financial Analysis
• Recent Developments
• Merger and Acquisitions
• SWOT Analysis

1. QIAGEN
2. Illumina, Inc.
3. F. Hoffmann-La Roche Ltd.
4. Agilent Technologies, Inc.
5. Myriad Genetics, Inc.
6. Koninklijke Philips N.V.
7. Abbott
8. Hitachi, Ltd.
9. Danaher
10. Prestige Biopharma Ltd.
11. BioMarker Strategies
12. Asuragen, Inc.
13. Others

 

Conclusion

The pancreatic cancer diagnostic market is experiencing steady growth, driven by rising cancer incidence, increasing awareness of early detection, and rapid technological advancements such as molecular diagnostics, liquid biopsies, and AI integration. Enhanced screening programs and government initiatives further support market expansion. Despite challenges like high costs and technical complexity, ongoing innovation and strategic collaborations are improving diagnostic accuracy and accessibility. These factors position the market for continued sustainable growth, emphasizing early diagnosis and personalized treatment for better patient outcomes.

 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter